Form 4: Oncolytics Biotech Director Granted Stock Options

Oncolytics Biotech Inc. reports the grant of stock options to Director Stephen C. Glover, with an exercise price tied to the stock's closing price on the grant date.

Summary

• Stephen C. Glover, a Director at Oncolytics Biotech Inc., was granted 96,000 stock options on June 1, 2026.
• The exercise price of these options is $1.06, equivalent to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the grant date.
• These options vest in three equal annual installments, with the first tranche vesting on June 1, 2027, contingent upon Mr. Glover's continued service.
• The options have an expiration date of June 1, 2036.
• This transaction is reported under SEC Form 4, indicating a change in beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation practice for a director rather than a significant financial event or strategic shift for the company.

Positives

• Director Stephen C. Glover has been granted stock options, aligning his interests with shareholders.
• The grant of options with an exercise price at market value suggests a belief in future stock appreciation.
• The vesting schedule encourages continued service and commitment from the Director.

Risks

• The value of the stock options is directly tied to the future performance of Oncolytics Biotech Inc.'s stock price.
• If the stock price does not appreciate above the exercise price of $1.06, the options may not become profitable.
• Vesting is contingent on continued service, meaning the options could be forfeited if the Director leaves the company before vesting.

Future Outlook

The grant of stock options with an exercise price at the current market value suggests management's expectation of future stock price appreciation. The vesting schedule indicates a commitment to retaining key personnel.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology sector to incentivize leadership and align their financial interests with those of shareholders, particularly in companies focused on long-term development and market growth.

Related Party Transactions

• Grant of stock options to Director Stephen C. Glover.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock performance can be viewed positively, as it incentivizes management to drive shareholder value. However, dilution could occur if options are exercised.
• Employees: The grant may indirectly signal confidence in the company's future, potentially boosting morale.
• Management: Director Stephen C. Glover benefits from potential future gains tied to the company's stock performance.

Next Steps

• Continued service by Stephen C. Glover to meet vesting requirements.
• Monitoring of Oncolytics Biotech Inc.'s stock performance relative to the option exercise price.

Key Dates

Keywords

stock options, Oncolytics Biotech, Stephen C. Glover, Director, SEC Form 4, beneficial ownership, grant date, exercise price, vesting schedule